Rifaximin

Czech version

Authors: M. Bortlík
Authors‘ workplace: Interní klinika 1. LF UK a ÚVN Praha ; Farmakologický ústav, 1. LF UK a VFN v Praze ; Klinické a výzkumné centrum pro střevní záněty ISCARE I. V. F. a. s., Praha
Published in: Gastroent Hepatol 2017; 71(3): 271-272
Category: Drug Profile
doi: https://doi.org/10.14735/amgh2017271

Sources

1. Lukáš M, Donoval R. Rifaximinum. Remedia 2005; 15 : 355–361.

2. Shayto RH, Abou Mrad R, Sharara AI. Use of rifaximin in gastrointestinal and liver diseases. World J Gastroenterol 2016; 22 (29): 6638–6651. doi: 10.3748/wjg.v22.i29.6638.

3. Ďuricová D, Bortlík M, Lukáš M. Rifaximin v terapii Crohnovy nemoci. Výsledky studie GRACE 02. Čes a Slov Gastroent a Hepatol 2010; 64 (3): 31–36.

4. Špičák J, Suchánková G, Kučera M. Diver-tikulární choroba. Gastroenterol Hepatol 2014; 68 (4): 307–318.

5. Colecchia A, Vestito A, Pasqui F et al. Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease. World J Gastroenterol 2007; 13 (2): 264–269.

6. Bianchi M, Festa V, Moretti A et al. Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease. Aliment Pharmacol Ther 2011; 33 (8) : 902–910. doi: 10.1111/ j.1365-2036.2011.04606.x.